KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Accumulated Expenses (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Accumulated Expenses for 4 consecutive years, with $114.9 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Accumulated Expenses changed N/A year-over-year to $114.9 million, compared with a TTM value of $114.9 million through Sep 2023, changed N/A, and an annual FY2022 reading of $114.7 million, up 22.89% over the prior year.
  • Accumulated Expenses was $114.9 million for Q3 2023 at Ginkgo Bioworks Holdings, up from $110.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $122.6 million in Q1 2023 and bottomed at $30.5 million in Q4 2020.
  • Average Accumulated Expenses over 4 years is $88.8 million, with a median of $93.3 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 205.96% in 2021, then grew 22.89% in 2022.
  • Year by year, Accumulated Expenses stood at $30.5 million in 2020, then surged by 205.96% to $93.3 million in 2021, then increased by 22.89% to $114.7 million in 2022, then increased by 0.22% to $114.9 million in 2023.
  • Business Quant data shows Accumulated Expenses for DNA at $114.9 million in Q3 2023, $110.5 million in Q2 2023, and $122.6 million in Q1 2023.